EFFICIENCY AND SAFETY OF MELATONIN ADMINISTRATION IN THE PATIENTS WITH ATOPIC DERMATITIS
Abstract. The objective of this study was to determine efficacy and safety of melatonin administered in addition to conventional atopic dermatitis treatment. Study design: open randomized parallel group study. Patients and treatment: Forty-six patients with exacerbation of moderate-to-severe atopic...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists
2014-07-01
|
| Series: | Медицинская иммунология |
| Subjects: | |
| Online Access: | https://www.mimmun.ru/mimmun/article/view/579 |
| _version_ | 1797198053128536064 |
|---|---|
| author | V. S. Shirinsky V. M. Nepomnyashikh M. I. Leonova O. L. Krugleeva V. S. Kozhevnikov N. Yu. Solovyova A. V. Shurlygina G. I. Litvinenko I. V. Shirinsky O. A. Malysheva |
| author_facet | V. S. Shirinsky V. M. Nepomnyashikh M. I. Leonova O. L. Krugleeva V. S. Kozhevnikov N. Yu. Solovyova A. V. Shurlygina G. I. Litvinenko I. V. Shirinsky O. A. Malysheva |
| author_sort | V. S. Shirinsky |
| collection | DOAJ |
| description | Abstract. The objective of this study was to determine efficacy and safety of melatonin administered in addition to conventional atopic dermatitis treatment. Study design: open randomized parallel group study. Patients and treatment: Forty-six patients with exacerbation of moderate-to-severe atopic dermatitis were included into the study. The patients were randomized, to receive either complex conventional treatment, or conventional treatment plus melatonin at a daily dose of 3 mg, being administered at 9 P.M. Primary endpoint of the study: Severity scoring using SCORAD index. Assessment of pharmacological effects included counting functional evaluation of T-cells, B-cells and phagocytes, as well as morning and evening serum levels of IgE, IL-4 and IFN-γ. Results. In melatonin group, a statistically significant SCORAD index reduction was revealed, as compared with conventionally treated group (84% vs 60%). Addition of melatonin to conventional treatment caused a 63 per cent decrease in relative risks of unfavorable outcome, defined as absence of 20 per cent improvement by the SCORAD scale. Clinical improvement in melatonin group was associated with increase in CD8+cell counts, IgM levels and indices of Fc-dependent monocyte and neutrophil phagocytosis. Circulating IgE and IL-4 levels did significantly decrease. In melatonin group, there were significant differences between the morning and evening counts of CD3+, CD4+, CD8+, CD16+ cells, like as levels of circulating IFN-γ. These preliminary data suggest efficacy of melatonin administration in the patients with atopic dermatitis. Further research is needed to confirm these results. |
| first_indexed | 2024-03-08T05:51:08Z |
| format | Article |
| id | doaj.art-dd8914fdf2b04aa4b39b32fa1c9ff084 |
| institution | Directory Open Access Journal |
| issn | 1563-0625 2313-741X |
| language | Russian |
| last_indexed | 2024-04-24T06:53:44Z |
| publishDate | 2014-07-01 |
| publisher | St. Petersburg branch of the Russian Association of Allergologists and Clinical Immunologists |
| record_format | Article |
| series | Медицинская иммунология |
| spelling | doaj.art-dd8914fdf2b04aa4b39b32fa1c9ff0842024-04-22T13:07:38ZrusSt. Petersburg branch of the Russian Association of Allergologists and Clinical ImmunologistsМедицинская иммунология1563-06252313-741X2014-07-0185-670771410.15789/1563-0625-2006-5-6-707-714576EFFICIENCY AND SAFETY OF MELATONIN ADMINISTRATION IN THE PATIENTS WITH ATOPIC DERMATITISV. S. Shirinsky0V. M. Nepomnyashikh1M. I. Leonova2O. L. Krugleeva3V. S. Kozhevnikov4N. Yu. Solovyova5A. V. Shurlygina6G. I. Litvinenko7I. V. Shirinsky8O. A. Malysheva9ГУ НИИ клинической иммунологии СО РАМНГУ НИИ клинической иммунологии СО РАМНГУ НИИ клинической иммунологии СО РАМНГУ НИИ клинической иммунологии СО РАМНГУ НИИ клинической иммунологии СО РАМНГУ НИИ клинической иммунологии СО РАМНГУ НИИ клинической иммунологии СО РАМНГУ НИИ клинической иммунологии СО РАМНГУ НИИ клинической иммунологии СО РАМНГУ НИИ клинической иммунологии СО РАМНAbstract. The objective of this study was to determine efficacy and safety of melatonin administered in addition to conventional atopic dermatitis treatment. Study design: open randomized parallel group study. Patients and treatment: Forty-six patients with exacerbation of moderate-to-severe atopic dermatitis were included into the study. The patients were randomized, to receive either complex conventional treatment, or conventional treatment plus melatonin at a daily dose of 3 mg, being administered at 9 P.M. Primary endpoint of the study: Severity scoring using SCORAD index. Assessment of pharmacological effects included counting functional evaluation of T-cells, B-cells and phagocytes, as well as morning and evening serum levels of IgE, IL-4 and IFN-γ. Results. In melatonin group, a statistically significant SCORAD index reduction was revealed, as compared with conventionally treated group (84% vs 60%). Addition of melatonin to conventional treatment caused a 63 per cent decrease in relative risks of unfavorable outcome, defined as absence of 20 per cent improvement by the SCORAD scale. Clinical improvement in melatonin group was associated with increase in CD8+cell counts, IgM levels and indices of Fc-dependent monocyte and neutrophil phagocytosis. Circulating IgE and IL-4 levels did significantly decrease. In melatonin group, there were significant differences between the morning and evening counts of CD3+, CD4+, CD8+, CD16+ cells, like as levels of circulating IFN-γ. These preliminary data suggest efficacy of melatonin administration in the patients with atopic dermatitis. Further research is needed to confirm these results.https://www.mimmun.ru/mimmun/article/view/579melatoninimmune statusatopic dermatitistreatment efficacy |
| spellingShingle | V. S. Shirinsky V. M. Nepomnyashikh M. I. Leonova O. L. Krugleeva V. S. Kozhevnikov N. Yu. Solovyova A. V. Shurlygina G. I. Litvinenko I. V. Shirinsky O. A. Malysheva EFFICIENCY AND SAFETY OF MELATONIN ADMINISTRATION IN THE PATIENTS WITH ATOPIC DERMATITIS Медицинская иммунология melatonin immune status atopic dermatitis treatment efficacy |
| title | EFFICIENCY AND SAFETY OF MELATONIN ADMINISTRATION IN THE PATIENTS WITH ATOPIC DERMATITIS |
| title_full | EFFICIENCY AND SAFETY OF MELATONIN ADMINISTRATION IN THE PATIENTS WITH ATOPIC DERMATITIS |
| title_fullStr | EFFICIENCY AND SAFETY OF MELATONIN ADMINISTRATION IN THE PATIENTS WITH ATOPIC DERMATITIS |
| title_full_unstemmed | EFFICIENCY AND SAFETY OF MELATONIN ADMINISTRATION IN THE PATIENTS WITH ATOPIC DERMATITIS |
| title_short | EFFICIENCY AND SAFETY OF MELATONIN ADMINISTRATION IN THE PATIENTS WITH ATOPIC DERMATITIS |
| title_sort | efficiency and safety of melatonin administration in the patients with atopic dermatitis |
| topic | melatonin immune status atopic dermatitis treatment efficacy |
| url | https://www.mimmun.ru/mimmun/article/view/579 |
| work_keys_str_mv | AT vsshirinsky efficiencyandsafetyofmelatoninadministrationinthepatientswithatopicdermatitis AT vmnepomnyashikh efficiencyandsafetyofmelatoninadministrationinthepatientswithatopicdermatitis AT mileonova efficiencyandsafetyofmelatoninadministrationinthepatientswithatopicdermatitis AT olkrugleeva efficiencyandsafetyofmelatoninadministrationinthepatientswithatopicdermatitis AT vskozhevnikov efficiencyandsafetyofmelatoninadministrationinthepatientswithatopicdermatitis AT nyusolovyova efficiencyandsafetyofmelatoninadministrationinthepatientswithatopicdermatitis AT avshurlygina efficiencyandsafetyofmelatoninadministrationinthepatientswithatopicdermatitis AT gilitvinenko efficiencyandsafetyofmelatoninadministrationinthepatientswithatopicdermatitis AT ivshirinsky efficiencyandsafetyofmelatoninadministrationinthepatientswithatopicdermatitis AT oamalysheva efficiencyandsafetyofmelatoninadministrationinthepatientswithatopicdermatitis |